Brenus Pharma is a French private biotech company developing a new class of multispecific immunotherapies targeting tumor antigens involved in escape mechanism. Brenus Technology mimicking relapsing patient's conditions and educate the immune system to anticipate tumor plasticity. We provide solutions to unmet needs in oncology, especially in solid tumors with a next gen I/O based on ADAPTIVE & MULTISPECIFIC TARGETS We have many ambitions for the future after key milestones we passed these past year: - Finalization of our preclinical package for the lead candidate backed by Top KOL in immuno oncology in EU/US, with very positive DATA presented in international congress (AACR, SITC. See the attached document). - FDA Pre IND and EMA Scientific advices passed, - Manufacturing readiness in GMP: First in Human starting in less than 15 months (Phase 1/2 trial in 2024 in EU and US in 1st line mCRC in combination with SOC, including Checkpoint Inhibitors). We are now opening our Series A round with the objective to raise 35M€ and close it around April/May 23.